- Home
- RDHL vs ACON Comparison
RDHL vs ACON Comparison
Compare RDHL & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- ACON
- Stock Information
- Founded
- RDHL 2009
- ACON 2008
- Country
- RDHL Israel
- ACON United States
- Employees
- RDHL N/A
- ACON N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- RDHL Health Care
- ACON Technology
- Exchange
- RDHL Nasdaq
- ACON Nasdaq
- Market Cap
- RDHL 3.9M
- ACON 4.4M
- IPO Year
- RDHL N/A
- ACON 2022
- Fundamental
- Price
- RDHL $1.88
- ACON $8.05
- Analyst Decision
- RDHL
- ACON Buy
- Analyst Count
- RDHL 0
- ACON 2
- Target Price
- RDHL N/A
- ACON $22.00
- AVG Volume (30 Days)
- RDHL 2.9M
- ACON 18.5K
- Earning Date
- RDHL 09-05-2025
- ACON 11-13-2025
- Dividend Yield
- RDHL N/A
- ACON N/A
- EPS Growth
- RDHL N/A
- ACON N/A
- EPS
- RDHL N/A
- ACON N/A
- Revenue
- RDHL $9,550,000.00
- ACON $62,948.00
- Revenue This Year
- RDHL $381.91
- ACON $145.39
- Revenue Next Year
- RDHL N/A
- ACON $145.45
- P/E Ratio
- RDHL N/A
- ACON N/A
- Revenue Growth
- RDHL 157.62
- ACON 16.68
- 52 Week Low
- RDHL $1.06
- ACON $6.20
- 52 Week High
- RDHL $9.00
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- RDHL 52.80
- ACON 55.98
- Support Level
- RDHL $1.89
- ACON $7.25
- Resistance Level
- RDHL $2.61
- ACON $9.57
- Average True Range (ATR)
- RDHL 0.23
- ACON 0.57
- MACD
- RDHL 0.01
- ACON -0.04
- Stochastic Oscillator
- RDHL 22.22
- ACON 34.45
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.